Payment overview · 2025
General Payments
$260.35
11 reported records · 10 companies
Healthcare provider profile · identity verified
John Matthew Weeman, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BARBERTON, OH · NPI 1801230222
Verified facts
What the public records show
CMS Open Payments records show John Matthew Weeman, M.D. received $260.35 in general payments during 2025 across 11 reported records.
Inspire Medical Systems, Inc. accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $49.52 | 19.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $40.75 | 15.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $35.85 | 13.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.44 | 9.4% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $21.37 | 8.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.46 | 7.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.94 | 7.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.18 | 7.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.99 | 5.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.85 | 5.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $260.35 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $49.52 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $40.75 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $24.44 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.99 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 464 | 167 |
| Amlodipine Besylate | Amlodipine Besylate | 363 | 130 |
| Levothyroxine Sodium | Levothyroxine Sodium | 325 | 101 |
| Lisinopril | Lisinopril | 320 | 110 |
| Gabapentin | Gabapentin | 236 | 58 |
| Omeprazole | Omeprazole | 236 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 230 | 77 |
| Losartan Potassium | Losartan Potassium | 225 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 208 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 159 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 152 | 54 |
| Metformin Hcl Er | Metformin Hcl | 146 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 136 | 46 |
| Metformin Hcl | Metformin Hcl | 126 | 43 |
| Eliquis | Apixaban | 123 | 34 |
| Furosemide | Furosemide | 115 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 35 |
| Carvedilol | Carvedilol | 98 | 37 |
| Pregabalin | Pregabalin | 96 | 20 |
| Trazodone Hcl | Trazodone Hcl | 95 | 37 |
| Simvastatin | Simvastatin | 93 | 36 |
| Ozempic | Semaglutide | 85 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 24 |
| Potassium Chloride | Potassium Chloride | 67 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 18 |
| Jardiance | Empagliflozin | 65 | 17 |
| Prednisone | Prednisone | 61 | 29 |
| Chlorthalidone | Chlorthalidone | 60 | 22 |
| Alendronate Sodium | Alendronate Sodium | 58 | 18 |
| Trulicity | Dulaglutide | 58 | 13 |
| Buspirone Hcl | Buspirone Hcl | 57 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 17 |
| Glimepiride | Glimepiride | 54 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 54 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 20 |
| Meloxicam | Meloxicam | 52 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 16 |
| Alprazolam | Alprazolam | 49 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 14 |
| Allopurinol | Allopurinol | 46 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 39 |
| Lorazepam | Lorazepam | 41 | 14 |
| Montelukast Sodium | Montelukast Sodium | 41 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | 14 |
| Famotidine | Famotidine | 40 | 15 |
| Mirtazapine | Mirtazapine | 40 | 17 |
| Promethazine Hcl | Promethazine Hcl | 40 | 14 |
| Glipizide Er | Glipizide | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 17 |
| Sertraline Hcl | Sertraline Hcl | 39 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Atenolol | Atenolol | 38 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 14 |
| Spironolactone | Spironolactone | 37 | 14 |
| Celecoxib | Celecoxib | 36 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 30 |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Torsemide | Torsemide | 34 | 12 |
| Valsartan | Valsartan | 34 | suppressed |
| Azithromycin | Azithromycin | 33 | 31 |
| Bupropion Xl | Bupropion Hcl | 33 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | 13 |
| Methylprednisolone | Methylprednisolone | 31 | 26 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | 12 |
| Cephalexin | Cephalexin | 27 | 19 |
| Ibuprofen | Ibuprofen | 27 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | 12 |
| Glipizide | Glipizide | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | 15 |
| Diazepam | Diazepam | 21 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Nyamyc | Nystatin | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Sprintec | Norgestimate-Ethinyl Estradiol | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $260.35 · 11 records | Inspire Medical Systems, Inc. | AREXVY, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, GARDASIL 9, INSPIRE, MOUNJARO, SHINGRIX, The Cologuard Plus Collection Kit, VRAYLAR, XIFAXAN, Xelstrym | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error